Amarin Stock Price, News & Analysis (NASDAQ:AMRN)

$3.97 -0.01 (-0.25 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$3.97
Today's Range$3.93 - $4.02
52-Week Range$2.81 - $4.47
Volume1.13 million shs
Average Volume1.82 million shs
Market Capitalization$1.07 billion
P/E Ratio-14.70
Dividend YieldN/A
Beta0.62

About Amarin (NASDAQ:AMRN)

Amarin logoAmarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AMRN
CUSIPN/A
Phone+353-1-6699020

Debt

Debt-to-Equity Ratio-1.48%
Current Ratio1.63%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio-14.7037037037037
Forward P/E Ratio-18.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$130.08 million
Price / Sales8.27
Cash FlowN/A
Price / CashN/A
Book Value($0.12) per share
Price / Book-33.08

Profitability

Trailing EPS($0.27)
Net Income$-86,350,000.00
Net Margins-43.90%
Return on EquityN/A
Return on Assets-35.67%

Miscellaneous

Employees215
Outstanding Shares270,880,000

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $45.85 million. The business's revenue was up 45.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.08) earnings per share. View Amarin's Earnings History.

When will Amarin make its next earnings announcement?

Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Amarin.

Where is Amarin's stock going? Where will Amarin's stock price be in 2018?

3 equities research analysts have issued 12-month price objectives for Amarin's shares. Their forecasts range from $7.00 to $10.00. On average, they expect Amarin's share price to reach $9.00 in the next twelve months. View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:

  • 1. Cantor Fitzgerald analysts commented, "AMRN provided preliminary 2017 results and its 2018 outlook. The guidance underscores our view that AMRN will be one of the top performing stocks in our coverage universe this year. Please see our recent note for more details." (1/4/2018)
  • 2. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (1/2/2018)

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:

  • Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board (Age 67)
  • John F. Thero CPA, President, Chief Executive Officer, Assistant Secretary, Director (Age 56)
  • Michael Wayne Kalb CPA, Chief Financial Officer, Senior Vice President (Age 45)
  • Stephen B. Ketchum Ph.D., President - Research and Development, Senior Vice President, Chief Scientific Officer (Age 50)
  • Joseph T. Kennedy J.D., Senior Vice President, Chief Compliance Officer, General Counsel, Secretary (Age 47)
  • Aaron D. Berg, Senior Vice President - Marketing and Sales (Age 53)
  • Michael J. Farrell, Vice President - Finance (principal accounting officer and principal financial officer) (Age 37)
  • Craig B. Granowitz M.D., Ph.D., Chief Medical Officer
  • Mark W. Salyer, Chief Commercial Officer
  • Joseph S. Zakrzewski, Director (Age 54)

How do I buy Amarin stock?

Shares of Amarin can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of Amarin stock can currently be purchased for approximately $3.97.

How big of a company is Amarin?

Amarin has a market capitalization of $1.07 billion and generates $130.08 million in revenue each year. The biopharmaceutical company earns $-86,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Amarin employs 215 workers across the globe.

How can I contact Amarin?

Amarin's mailing address is Upper Pembroke Pembroke House 2, South Lotts Road, DUBLIN, FK7 9JQ, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6699020 or via email at [email protected]


MarketBeat Community Rating for Amarin (AMRN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  648
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amarin (NASDAQ:AMRN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.00$9.00$9.00$8.00
Price Target Upside: 114.80% upside154.24% upside163.93% upside107.25% upside

Amarin (NASDAQ:AMRN) Consensus Price Target History

Price Target History for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ:AMRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/4/2018Cantor FitzgeraldSet Price TargetBuy$10.00HighView Rating Details
11/2/2017HC WainwrightReiterated RatingBuy$10.00N/AView Rating Details
10/11/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/19/2016CitigroupInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Amarin (NASDAQ:AMRN) Earnings History and Estimates Chart

Earnings by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
11/1/2017Q3 2017($0.05)($0.04)$45.85 million$47.10 millionViewN/AView Earnings Details
8/2/20176/30/2017($0.06)($0.05)$40.35 million$44.95 millionViewListenView Earnings Details
5/4/20173/31/2017($0.07)($0.08)$37.85 million$34.60 millionViewListenView Earnings Details
2/28/201712/31/2016($0.09)($0.05)$36.13 million$38.40 millionViewListenView Earnings Details
11/3/2016Q316($0.10)($0.08)$32.03 million$32.40 millionViewN/AView Earnings Details
8/4/2016Q216($0.13)($0.07)$29.97 million$32.82 millionViewN/AView Earnings Details
5/5/2016Q116($0.11)($0.14)$26.77 million$25.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.08)($0.12)$23.62 million$26.40 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.18)$21.93 million$21.30 millionViewN/AView Earnings Details
8/6/2015Q2($0.12)($0.15)$19.10 million$17.70 millionViewN/AView Earnings Details
5/8/2015Q115($0.11)($0.18)$21.86 million$15.60 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.11)$17.40 million$16.50 millionViewN/AView Earnings Details
11/6/2014Q314($0.14)($0.18)$14.87 million$14.15 millionViewN/AView Earnings Details
8/7/2014Q214($0.15)($0.14)$12.86 million$12.60 millionViewN/AView Earnings Details
5/9/2014Q114($0.18)($0.17)$11.65 million$11.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.23)($0.26)$11.17 million$10.10 millionViewN/AView Earnings Details
11/7/2013($0.32)($0.25)$10.25 million$8.40 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.38)($0.26)$5.50 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.41)$5.21 million$2.34 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.28)($0.28)ViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.15)($0.24)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.09)($0.15)ViewN/AView Earnings Details
2/29/2012Q4 2011($0.08)($0.08)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.13)($0.10)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.12)$2.51ViewN/AView Earnings Details
5/10/2011Q1 2011($0.08)($0.05)ViewN/AView Earnings Details
3/16/2011Q4 2010($0.08)$0.17ViewN/AView Earnings Details
9/25/2008Q2 2008$0.01ViewN/AView Earnings Details
5/19/2008Q4 2007($0.61)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Amarin (NASDAQ:AMRN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.07)($0.07)($0.07)
Q2 20181($0.05)($0.05)($0.05)
Q3 20181($0.05)($0.05)($0.05)
Q4 20181($0.03)($0.03)($0.03)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Amarin (NASDAQ:AMRN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Amarin (NASDAQ AMRN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.72%
Institutional Ownership Percentage: 40.12%
Insider Trades by Quarter for Amarin (NASDAQ:AMRN)
Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Amarin (NASDAQ AMRN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018Joseph T KennedyGeneral CounselSell51,106$4.10$209,534.60View SEC Filing  
1/11/2018Steven B KetchumInsiderSell2,612$4.40$11,492.80View SEC Filing  
1/5/2018Steven B KetchumInsiderSell64,683$4.40$284,605.20View SEC Filing  
1/2/2018Steven B KetchumInsiderSell128,257$4.25$545,092.25View SEC Filing  
11/30/2017John F TheroInsiderBuy10,000$3.24$32,400.00View SEC Filing  
10/5/2017Steven B KetchumInsiderSell63,479$3.48$220,906.92View SEC Filing  
7/3/2017Joseph T. KennedyGeneral CounselSell307,911$4.00$1,231,644.00View SEC Filing  
2/1/2016John F TheroCEOBuy25,000$1.37$34,250.00661,743View SEC Filing  
8/11/2015John F TheroCEOBuy20,000$2.35$47,000.00View SEC Filing  
11/12/2014John F TheroInsiderBuy50,000$0.83$41,500.00View SEC Filing  
11/11/2014Michael James FarrellInsiderBuy5,500$0.84$4,620.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amarin (NASDAQ AMRN) News Headlines

Source:
DateHeadline
Wired News – Amarin Initiates Clinical Development of VASCEPA in Mainland ChinaWired News – Amarin Initiates Clinical Development of VASCEPA in Mainland China
finance.yahoo.com - January 19 at 3:14 PM
Insider Selling: Amarin Co. plc (AMRN) General Counsel Sells 51,106 Shares of StockInsider Selling: Amarin Co. plc (AMRN) General Counsel Sells 51,106 Shares of Stock
www.americanbankingnews.com - January 17 at 7:04 PM
Amarin Announces Commencement of VASCEPA® Clinical Development in Mainland ChinaAmarin Announces Commencement of VASCEPA® Clinical Development in Mainland China
finance.yahoo.com - January 17 at 11:47 AM
Amarin Co. plc (AMRN) Insider Steven B. Ketchum Sells 2,612 SharesAmarin Co. plc (AMRN) Insider Steven B. Ketchum Sells 2,612 Shares
www.americanbankingnews.com - January 16 at 7:42 PM
Amarin Co. plc (AMRN) Receives Average Recommendation of "Buy" from AnalystsAmarin Co. plc (AMRN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 16 at 1:38 AM
Critical Analysis: Amarin (AMRN) vs. Regeneron Pharmaceuticals (REGN)Critical Analysis: Amarin (AMRN) vs. Regeneron Pharmaceuticals (REGN)
www.americanbankingnews.com - January 14 at 1:08 AM
Amarin Co. plc (AMRN) Insider Sells $284,605.20 in StockAmarin Co. plc (AMRN) Insider Sells $284,605.20 in Stock
www.americanbankingnews.com - January 9 at 7:16 PM
Amarin Co. plc Expected to Post Q1 2018 Earnings of ($0.07) Per Share (AMRN)Amarin Co. plc Expected to Post Q1 2018 Earnings of ($0.07) Per Share (AMRN)
www.americanbankingnews.com - January 8 at 5:36 AM
Head to Head Comparison: Amarin (AMRN) & MEI Pharma (MEIP)Head to Head Comparison: Amarin (AMRN) & MEI Pharma (MEIP)
www.americanbankingnews.com - January 5 at 1:44 PM
Amarin Provides Preliminary 2017 Results and Provides 2018 ... - GlobeNewswire (press release)Amarin Provides Preliminary 2017 Results and Provides 2018 ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:06 AM
Company Update (NASDAQ:AMRN): Amarin Corporation plc Provides Preliminary 2017 Results and Provides 2018 OutlookCompany Update (NASDAQ:AMRN): Amarin Corporation plc Provides Preliminary 2017 Results and Provides 2018 Outlook
finance.yahoo.com - January 5 at 5:06 AM
Amarin Provides Preliminary 2017 Results and Provides 2018 OutlookAmarin Provides Preliminary 2017 Results and Provides 2018 Outlook
finance.yahoo.com - January 5 at 5:06 AM
Insider Selling: Amarin Co. plc (AMRN) Insider Sells 128,257 Shares of StockInsider Selling: Amarin Co. plc (AMRN) Insider Sells 128,257 Shares of Stock
www.americanbankingnews.com - January 4 at 9:28 PM
Cantor Fitzgerald Reaffirms "Buy" Rating for Amarin (AMRN)Cantor Fitzgerald Reaffirms "Buy" Rating for Amarin (AMRN)
www.americanbankingnews.com - January 4 at 8:54 PM
Amarin (AMRN) Upgraded to Hold by Zacks Investment ResearchAmarin (AMRN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - January 2 at 5:56 PM
Amarin (AMRN) Rating Increased to Buy at BidaskClubAmarin (AMRN) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - December 29 at 12:36 PM
Amarin (AMRN) Upgraded to Hold at BidaskClubAmarin (AMRN) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - December 23 at 5:04 PM
Amarin Co. plc (AMRN) Expected to Announce Quarterly Sales of $50.30 MillionAmarin Co. plc (AMRN) Expected to Announce Quarterly Sales of $50.30 Million
www.americanbankingnews.com - December 23 at 2:25 AM
Amarin Co. plc to Post FY2019 Earnings of ($0.05) Per Share, Jefferies Group Forecasts (AMRN)Amarin Co. plc to Post FY2019 Earnings of ($0.05) Per Share, Jefferies Group Forecasts (AMRN)
www.americanbankingnews.com - December 22 at 7:31 PM
Amarin Co. plc (AMRN) Given Average Recommendation of "Hold" by AnalystsAmarin Co. plc (AMRN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 22 at 1:34 AM
-$0.04 Earnings Per Share Expected for Amarin Co. plc (AMRN) This Quarter-$0.04 Earnings Per Share Expected for Amarin Co. plc (AMRN) This Quarter
www.americanbankingnews.com - December 21 at 11:54 PM
Amarin Co. plc Forecasted to Earn FY2020 Earnings of $0.07 Per Share (AMRN)Amarin Co. plc Forecasted to Earn FY2020 Earnings of $0.07 Per Share (AMRN)
www.americanbankingnews.com - December 21 at 11:26 PM
Amarin (AMRN) Stock Rating Upgraded by ValuEngineAmarin (AMRN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
Amarin (AMRN) Downgraded by Zacks Investment ResearchAmarin (AMRN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 20 at 8:06 PM
Amarin (AMRN) Says REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March - StreetInsider.comAmarin (AMRN) Says REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March - StreetInsider.com
www.streetinsider.com - December 20 at 5:05 AM
Amarin (AMRN) Given a $10.00 Price Target at Cantor FitzgeraldAmarin (AMRN) Given a $10.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 19 at 6:08 PM
ETFs with exposure to Amarin Corp. Plc : December 19, 2017ETFs with exposure to Amarin Corp. Plc : December 19, 2017
finance.yahoo.com - December 19 at 3:12 PM
Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018Amarin Announces REDUCE-IT Cardiovascular Outcomes Study Final Patient Visits to Commence in March 2018
finance.yahoo.com - December 19 at 3:12 PM
Amarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San FranciscoAmarin to Present at 36th Annual J.P. Morgan Healthcare Conference in San Francisco
finance.yahoo.com - December 19 at 5:15 AM
Amarin (AMRN) PT Set at $10.00 by Cantor FitzgeraldAmarin (AMRN) PT Set at $10.00 by Cantor Fitzgerald
www.americanbankingnews.com - December 6 at 6:26 PM
Amarin Co. plc (AMRN) Expected to Post Quarterly Sales of $50.30 MillionAmarin Co. plc (AMRN) Expected to Post Quarterly Sales of $50.30 Million
www.americanbankingnews.com - December 6 at 6:22 PM
Amarin Co. plc (AMRN) Insider Acquires $32,400.00 in StockAmarin Co. plc (AMRN) Insider Acquires $32,400.00 in Stock
www.americanbankingnews.com - December 4 at 11:42 AM
Zacks: Brokerages Anticipate Amarin Co. plc (AMRN) Will Announce Earnings of -$0.04 Per ShareZacks: Brokerages Anticipate Amarin Co. plc (AMRN) Will Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - December 4 at 1:32 AM
ETFs with exposure to Amarin Corp. Plc : November 28, 2017ETFs with exposure to Amarin Corp. Plc : November 28, 2017
finance.yahoo.com - November 28 at 3:07 PM
Amarin Co. plc (AMRN) Given Average Rating of "Hold" by BrokeragesAmarin Co. plc (AMRN) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 27 at 2:06 AM
Comparing Amarin Corporation PLC (AMRN) and Imprimis Pharmaceuticals (IMMY)Comparing Amarin Corporation PLC (AMRN) and Imprimis Pharmaceuticals (IMMY)
www.americanbankingnews.com - November 23 at 5:46 PM
Amarin Corporation PLC (AMRN) versus Its Competitors Head-To-Head ReviewAmarin Corporation PLC (AMRN) versus Its Competitors Head-To-Head Review
www.americanbankingnews.com - November 22 at 11:31 AM
Zacks: Analysts Anticipate Amarin Corporation PLC (AMRN) Will Post Quarterly Sales of $50.30 MillionZacks: Analysts Anticipate Amarin Corporation PLC (AMRN) Will Post Quarterly Sales of $50.30 Million
www.americanbankingnews.com - November 17 at 4:52 AM
ValuEngine Downgrades Amarin Corporation PLC (AMRN) to SellValuEngine Downgrades Amarin Corporation PLC (AMRN) to Sell
www.americanbankingnews.com - November 17 at 12:56 AM
Amarin: A Likely Runner In 2018 - Seeking AlphaAmarin: A Likely Runner In 2018 - Seeking Alpha
seekingalpha.com - November 16 at 4:04 PM
Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular RiskReal World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk
finance.yahoo.com - November 14 at 9:24 PM
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney DiseaseVascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease
finance.yahoo.com - November 14 at 2:39 AM
Cantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price TargetCantor Fitzgerald Analysts Give Amarin Corporation PLC (AMRN) a $10.00 Price Target
www.americanbankingnews.com - November 13 at 4:30 PM
Amarin Corporation PLC (AMRN) Expected to Post Q4 2017 Earnings of ($0.06) Per ShareAmarin Corporation PLC (AMRN) Expected to Post Q4 2017 Earnings of ($0.06) Per Share
www.americanbankingnews.com - November 8 at 4:34 PM
Drug Makers Stock Performance Review -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release)Drug Makers Stock Performance Review -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release)
www.prnewswire.com - November 8 at 3:27 PM
Amarin to Present at the Jefferies London Healthcare Conference - GlobeNewswire (press release)Amarin to Present at the Jefferies London Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 8 at 3:27 PM
Amarin Corporation PLC Expected to Post FY2017 Earnings of ($0.22) Per Share (AMRN)Amarin Corporation PLC Expected to Post FY2017 Earnings of ($0.22) Per Share (AMRN)
www.americanbankingnews.com - November 8 at 12:30 PM
ETFs with exposure to Amarin Corp. Plc : November 6, 2017ETFs with exposure to Amarin Corp. Plc : November 6, 2017
finance.yahoo.com - November 6 at 4:39 PM
Jefferies Group Research Analysts Cut Earnings Estimates for Amarin Corporation PLC (AMRN)Jefferies Group Research Analysts Cut Earnings Estimates for Amarin Corporation PLC (AMRN)
www.americanbankingnews.com - November 6 at 1:58 PM
Brokers Issue Forecasts for Amarin Corporation PLCs Q4 2017 Earnings (AMRN)Brokers Issue Forecasts for Amarin Corporation PLC's Q4 2017 Earnings (AMRN)
www.americanbankingnews.com - November 6 at 9:49 AM

SEC Filings

Amarin (NASDAQ:AMRN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amarin (NASDAQ:AMRN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amarin (NASDAQ AMRN) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.